Pfizer to disclose clinical trial payments

By Nick Taylor

- Last updated on GMT

Related tags Clinical trial Pfizer

Pfizer has preempted the Sunshine Act by promising to disclose payments made to principal investigators, major academic institutions and research sites involved in Phase I to IV trials.

The intention is to publish all payments to an individual or institution that exceed $500 a year and non-monetary items, for example meals, that cost over $25. Also covered under Pfizer’s action are payments to US doctors for consulting and speeches.

This measure goes further towards full disclosure than any other drug maker but it still falls short of the level that would be required if the Physician Payments Sunshine Act of 2009 is passed into law.

Under the terms of the Act drug companies would have to disclose all payments exceeding $100 a year and would face a fine of up to $1m for failure to comply.

Despite Pfizer falling short of the values in the Act the move has been welcomed by Senator Grassley who co-sponsored the legislation. Steve Nissen, chairman of cardiovascular medicine at the Cleveland Clinic and vocal critic of the industry, has also commended Pfizer.

Both regard Pfizer’s move as a step in the right direction but would still welcome the Act and the $100 limit it brings. However, even with the higher limit scandals such as the $308,000 one doctor received to promote Neurontin at conferences should be exposed quickly.

Information will be displayed on Pfizer’s website by early in 2010 and cover all payments made from July 2009 onwards.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us

Products

View more

Webinars